Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Plinabulin, a Novel Small Molecule That Ameliorates Chemotherapy-Induced Neutropenia, Is Administered on the Same Day of Chemotherapy and Has Anticancer Efficacy

Douglas W Blayney, MD, Lyudmila Bazhenova, MD, G. Kenneth Lloyd, PhD, Lan Huang, PhD, Ramon Mohanlal, MD PhD

Blood (2016) 128 (22): 2508.

https://doi.org/10.1182/blood.V128.22.2508.2508

Published: 2016

Journal Articles

Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1

Paul G. Richardson, Todd M. Zimmerman, Craig C. Hofmeister, Moshe Talpaz, Asher A. Chanan-Khan, Jonathan L. Kaufman, Jacob P. Laubach, Dharminder Chauhan, Andrzej J. Jakubowiak, Steven Reich, Mohit Trikha, Kenneth C. Anderson

Blood (2016) 127 (22): 2693–2700.

https://doi.org/10.1182/blood-2015-12-686378

Published: 2016

Journal Articles

Marizomib Overcomes Compensatory Hyperactivation of Trypsin-like and Caspase-like Subunits to Provide Pan-Proteasome Subunit Inhibition in Patients with Multiple Myeloma and Solid Tumors

Andrew Spencer, Simon Harrison, MD, Francis Burrows, Paul Mainwaring, MD, Timothy Price, MD, Michael J Millward, MD, Peeter Padrik, MD, Craig Underhill, MD, Paul Cannell, MD, Steven D Reich, MD, Mohit Trikha, PhD

Blood (2015) 126 (23): 5375.

https://doi.org/10.1182/blood.V126.23.5375.5375

Published: 2015

Journal Articles

Phase 1, Multicenter, Open-Label, Combination Study (NPI-0052-107; NCT02103335) of Pomalidomide (POM), Marizomib (MRZ, NPI-0052), and Low-Dose Dexamethasone (LD-DEX) in Patients with Relapsed and Refractory Multiple Myeloma

Andrew Spencer, Jacob P. Laubach, MD, Jeffrey A Zonder, MD, Ashraf Z Badros, MD, Simon Harrison, MD, Amit Khot, MD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD, Steven D Reich, MD, Mohit Trikha, PhD, Paul G. Richardson, MD

Blood (2015) 126 (23): 4220.

https://doi.org/10.1182/blood.V126.23.4220.4220

Published: 2015

Journal Articles

A Novel Acanthoic Acid Analog NPI-1342 Blocks IκB Kinase-α and Trigger In Vitro and In Vivo cytotoxicity in Multiple Myeloma Cells

Dharminder Chauhan, PhD, Ajita V. Singh, Arghya Ray, Ph.D, Teru Hideshima, MD, PhD, Paul G. Richardson, MD, Michael A. Palladino, PhD, Kenneth C. Anderson, MD

Blood (2011) 118 (21): 1841.

https://doi.org/10.1182/blood.V118.21.1841.1841

Published: 2011

Journal Articles

Liver Hypoxia and Tissue Injury Are Specific to Sickle Cell Mice in An Experimental Model of Sickle Cell Vaso-Occlusion.

Lewis L. Hsu, MD, PhD, Audrey C Noguchi, Constance Noguchi, PhD, Katherine C Wood, Ph.D., James G Taylor, VI, MD, Gregory J. Kato, MD, Mark Gladwin, MD, Bhalchandra Diwan, PhD

Blood (2009) 114 (22): 2569.

https://doi.org/10.1182/blood.V114.22.2569.2569

Published: 2009

Journal Articles

Inhibition of the RKIP and PTEN-Transcription Repressor Snail in B-NHL by the Proteasome Inhibitor NPI-0052: Roles of RKIP and PTEN Induction in the Reversal of Resistance to TRAIL Apoptosis.

Stavroula Baritaki, Kam Yeung, Ph.D., Katherine Wu, Haiming Chen, MD, PhD, James R. Berenson, MD, Michael A. Palladino, PhD, Benjamin Bonavida, PhD

Blood (2009) 114 (22): 3938.

https://doi.org/10.1182/blood.V114.22.3938.3938

Published: 2009

Journal Articles

NPI-2358, a Novel Vascular Disrupting Agent Blocks Growth and Angiogenesis in Multiple Myeloma Cells.

Dharminder Chauhan, Ph.D, Ajita V. Singh, Madhavi Bandi, Noopur Raje, M.D., Robert L Schlossman, M.D., G. Kenneth Lloyd, PhD, Paul Richardson, Michael A. Palladino, PhD, Kenneth C. Anderson, MD

Blood (2009) 114 (22): 3842.

https://doi.org/10.1182/blood.V114.22.3842.3842

Published: 2009

Journal Articles

The Novel Proteasome Inhibitor NPI-0052 Induces the Expression of Raf-1 Kinase Inhibitor Protein RKIP) in B-NHL via Inhibition of the Transcription Repressor Snail: Roles of Snail and RKIP in Sensitization to TRAIL Apoptosis

Stavroula Baritaki, Aaron Chapman, Katherine Wu, Kam Yeung, Ph.D., Demetrios Spandidos, Ph.D., James R. Berenson, MD, Michael A. Palladino, MS, PhD, Benjamin Bonavida, PhD

Blood (2008) 112 (11): 2611.

https://doi.org/10.1182/blood.V112.11.2611.2611

Published: 2008

Journal Articles

Combination of a Novel Proteasome Inhibitor NPI-0052 and Lenalidomide Trigger in Vivo Synergistic Cytotoxicity in Multiple Myeloma

Dharminder Chauhan, PhD, Ajita V. Singh, Mohan Brahmandam, Giada Bianchi, Klaus Podar, Teru Hideshima, Nikhil Munshi, Paul Richardson, Michael A. Palladino, PhD, Kenneth C. Anderson

Blood (2008) 112 (11): 3662.

https://doi.org/10.1182/blood.V112.11.3662.3662

Published: 2008

Journal Articles

Synergy in Apoptosis Is Achieved in B-NHL by the Combination of Rituximab and the Novel Proteasome Inhibitor NPI-0052: Pivotal Role of Induction of the Immune Surveillance Cancer Gene Product RKIP

Mario I. Vega, PhD, Melisa Martinez- Paniagua, Sara Huerta-Yepez, PhD., Eriko Suzuki, Kazuo Umezawa, Kam Yeung, Ph.D., Massimo Libra, Stavroula Baritaki, Michael A. Palladino, PhD, Benjamin Bonavida, PhD

Blood (2008) 112 (11): 4973.

https://doi.org/10.1182/blood.V112.11.4973.4973

Published: 2008

Journal Articles

The Combination of Bortezomib and NPI-0052 Exerts Anti-Tumor Activity in Waldenstrom Macroglobulinemia (WM).

Aldo Roccaro, MD, Xavier Leleu, MD, Antonio Sacco, Xiaoying Jia, Anne-Sophie Moreau, MD, Hai Ngo, Abdelkareem Azab, Feda Azab, Evdoxia Hatjiharissi, MD, Steven Treon, MD, Teru Hideshima, MD, Michael Palladino, Kenneth Anderson, MD, Dharminder Chuahan, Irene Ghobrial, MD

Blood (2007) 110 (11): 1516.

https://doi.org/10.1182/blood.V110.11.1516.1516

Published: 2007

Journal Articles

Induction of Raf-1 Kinase Inhibitory Protein (RKIP) by the Proteasome Inhibitor NPI-0052 and Reversal of B-NHL Resistance to Apoptosis.

Stavroula Baritaki, Kam Yeung, Devasis Chatterjee, Michel Palladino, Benjamin Bonavida

Blood (2007) 110 (11): 809.

https://doi.org/10.1182/blood.V110.11.809.809

Published: 2007

Journal Articles

Distinct Dynamic Profiles for NPI-0052-And Bortezomib-Induced Apoptosis in Multiple Myeloma.

Dharminder Chauhan, PhD, Ajita Singh, Ph.D, Mugdha Velankar, M.S, Teru Hideshima, Ph.D, Huib Ovaa, Ph.D, Celia Berkers, M.S, Giada Bianchi, Ph.D, Roberto Sitia, M.D., Nikhil C. Munshi, M.D., Paul Richardson, M.D., Michael A. Palladino, Ph.D, Kenneth C. Anderson, M.D

Blood (2006) 108 (11): 3396.

https://doi.org/10.1182/blood.V108.11.3396.3396

Published: 2006

Journal Articles

Induction of RKIP and Inhibition of the Transcription Repressor YY1 in B-NHL by the Novel Proteasome Inhibitor NPI-0052 and Sensitization to TRAIL-Induced Apoptosis.

Eriko Suzuki, Sara Huerta-Yepez, Ph.D., Stavroula Baritaki, Ph.D., Michael Palladino, Ph.D., Benjamin Bonavida, Ph.D.

Blood (2006) 108 (11): 2391.

https://doi.org/10.1182/blood.V108.11.2391.2391

Published: 2006

Journal Articles

Requirement of Caspase-8 Versus Caspase-9 during Apoptosis in Multiple Myeloma Cells Induced by Bortezomib- or a Novel Proteasome Inhibitor NPI-0052.

Dharminder Chauhan, PhD, Laurence Catley, M.D, Mugdha Velankar, M.S, Anthony Letai, M.D, Teru Hideshima, Ph.D, Klaus Podar, M.D, Hiroshi Yasui, M.D, Nicholas Mitsiades, M.D, Constantine Mitsiades, M.D, Yu-Tzu Tai, Ph.D, Noopur Raje, M.D, Nikhil Munshi, M.D, Michael A. Palladino, Ph.D, Kenneth C. Anderson, M.D

Blood (2005) 106 (11): 3378.

https://doi.org/10.1182/blood.V106.11.3378.3378

Published: 2005

Journal Articles

Targeting Therapy for Resistant Multiple Myeloma with a Novel Inhibitor of NF-KB, NPI-1387.

Dharminder Chauhan, PhD, Ta-Hsiang Chao, Ph.D, Deli He, M.S, Teru Hideshima, Ph.D, Laurence Catley, M.D, Young-Ger Suh, Ph.D, Robert Schlossman, M.D, Saskia Neuteboom, Ph.D, Michael A. Palladino, Ph.D, Kenneth C. Anderson, M.D.

Blood (2005) 106 (11): 640.

https://doi.org/10.1182/blood.V106.11.640.640

Published: 2005

Journal Articles

A Novel Orally Available Proteasome Inhibitor NPI-0052 Induces Killing in Multiple Myeloma (MM) Cells Resistant to Conventional and Bortezomib Therapies.

Dharminder Chauhan, Ph.D, Guilan Li, M.S, Klaus Podar, Ph.D, Teru Hideshima, Ph.D, Reshma Shrigarpure, Ph.D, Laurence Catley, M.D, Constantine Mitsiades, Ph.D, Nikhil Munshi, M.D, Robert Sclossman, M.D, Rena Bahjat, Ph.D, Saskia Neuteboom, M.D., Paul Richardson, M.D, Michael Palladino, Ph.D, Kenneth C. Anderson, M.D

Blood (2004) 104 (11): 2405.

https://doi.org/10.1182/blood.V104.11.2405.2405

Published: 2004

NARROW

Plinabulin, a Novel Small Molecule That Ameliorates Chemotherapy-Induced Neutropenia, Is Administered on the Same Day of Chemotherapy and Has Anticancer Efficacy

Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1

Marizomib Overcomes Compensatory Hyperactivation of Trypsin-like and Caspase-like Subunits to Provide Pan-Proteasome Subunit Inhibition in Patients with Multiple Myeloma and Solid Tumors

Phase 1, Multicenter, Open-Label, Combination Study (NPI-0052-107; NCT02103335) of Pomalidomide (POM), Marizomib (MRZ, NPI-0052), and Low-Dose Dexamethasone (LD-DEX) in Patients with Relapsed and Refractory Multiple Myeloma

A Novel Acanthoic Acid Analog NPI-1342 Blocks IκB Kinase-α and Trigger In Vitro and In Vivo cytotoxicity in Multiple Myeloma Cells

Liver Hypoxia and Tissue Injury Are Specific to Sickle Cell Mice in An Experimental Model of Sickle Cell Vaso-Occlusion.

Inhibition of the RKIP and PTEN-Transcription Repressor Snail in B-NHL by the Proteasome Inhibitor NPI-0052: Roles of RKIP and PTEN Induction in the Reversal of Resistance to TRAIL Apoptosis.

NPI-2358, a Novel Vascular Disrupting Agent Blocks Growth and Angiogenesis in Multiple Myeloma Cells.

The Novel Proteasome Inhibitor NPI-0052 Induces the Expression of Raf-1 Kinase Inhibitor Protein RKIP) in B-NHL via Inhibition of the Transcription Repressor Snail: Roles of Snail and RKIP in Sensitization to TRAIL Apoptosis

Combination of a Novel Proteasome Inhibitor NPI-0052 and Lenalidomide Trigger in Vivo Synergistic Cytotoxicity in Multiple Myeloma

Synergy in Apoptosis Is Achieved in B-NHL by the Combination of Rituximab and the Novel Proteasome Inhibitor NPI-0052: Pivotal Role of Induction of the Immune Surveillance Cancer Gene Product RKIP

The Combination of Bortezomib and NPI-0052 Exerts Anti-Tumor Activity in Waldenstrom Macroglobulinemia (WM).

Induction of Raf-1 Kinase Inhibitory Protein (RKIP) by the Proteasome Inhibitor NPI-0052 and Reversal of B-NHL Resistance to Apoptosis.

Distinct Dynamic Profiles for NPI-0052-And Bortezomib-Induced Apoptosis in Multiple Myeloma.

Induction of RKIP and Inhibition of the Transcription Repressor YY1 in B-NHL by the Novel Proteasome Inhibitor NPI-0052 and Sensitization to TRAIL-Induced Apoptosis.

Requirement of Caspase-8 Versus Caspase-9 during Apoptosis in Multiple Myeloma Cells Induced by Bortezomib- or a Novel Proteasome Inhibitor NPI-0052.

Targeting Therapy for Resistant Multiple Myeloma with a Novel Inhibitor of NF-KB, NPI-1387.

A Novel Orally Available Proteasome Inhibitor NPI-0052 Induces Killing in Multiple Myeloma (MM) Cells Resistant to Conventional and Bortezomib Therapies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only